Abstract:Background: Primary triple-negative breast cancer (TNBC) is influenced by hypoxic microenvironments that promote metastasis and paclitaxel (PTX) resistance. However, few studies have attempted to understand how hypoxia promotes metastasis and drug resistance and provide a solution to these problems, especially in TNBC. Methods: Transcriptome sequencing of TNBC cells under hypoxic conditions was performed to identify C1QBP. The mechanism of HIF-1α induced C1QBP under both hypoxia and normoxia were investigated by ChIP-qPCR. Next the role of C1QBP in mediating metastasis and chemoresistance to PTX and regulating VCAM-1 were studied by in vitro and in vivo experiments. Then the anti-cancer effect of C1QBP inhibition in hypoxic environment was investigated. Furthermore, TCGA database and clinical tissue microarrays in our cohort were used to verify the correlation of C1QBP with the expression of HIF-1α, VCAM-1, and p65. Results: Here, we report that hypoxia-induced HIF-1α upregulated the expression of C1QBP; the inhibition of C1QBP notably blocked metastasis of TNBC cells and increased their sensitivity to PTX under hypoxic conditions in vitro and in vivo. Depletion of C1QBP decreased VCAM-1 expression by reducing p65 protein levels in the nucleus and, remarkably, suppressed the activation of hypoxia-induced PKC–NF-κβ signaling. Moreover, tissue microarray and immunohistochemical staining showed a positive correlation between the protein levels of C1QBP and that of p65 and VCAM-1 in breast cancer patients (especially TNBC). The analysis from TCGA database further confirmed the correlation between the mRNA levels of C1QBP, HIF-1α, and VCAM-1 in TNBC patients. Conclusions: Hypoxia-induced HIF-1α upregulates C1QBP expression of TNBC cells. Deregulated C1QBP may inhibit hypoxia-induced metastasis and PTX resistance along with reducing the activation of the PKC–NF-κβ–VCAM-1 axis. Targeting C1QBP in the presence of PTX may be a potential therapeutic against hypoxia-induced metastatic or drug resistant TNBC. Funding Statement: Haiyan Fund Project of Harbin Medical University Cancer Hospital (Grant number: JJQN 2018-06); Health Committee Fund Project of Heilongjiang Province (Grant number: 2019-056); National Natural Science Foundation of China, Grant/Award Numbers: 81972706; National Natural Science Foundation of China, Grant/Award Numbers: 81602639; National Natural Science Foundation of China, Grant/Award Numbers: 81602323; National Natural Science Foundation of China, Grant/Award Numbers: 81872149; Heilongjiang postdoctoral fundation (LBH-Z18222). Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation, Grant/Award Number: YQ2019H027; 9. Wu Lien‐ the Science Foundation of Harbin Medical University, Grant/Award Number: WLD‐ QN1706; Young Elite Training Foundation Grant of Harbin Medical University Cancer Hospital, Grant/Award Number: JY2016‐ 02; Distinguished Young Scholars of Harbin Medical University Cancer Hospital, Grant/Award Number: JCQN2018‐ 03.Declaration of Interests: The authors declare no conflict of interest. Ethics Approval Statement: The Medical Ethics Committee approved this study and all the relevant information was provided to the patients who were willing to participate in the study.

Hypoxia-Mediated C1QBP Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates VCAM-1 Expression Via Canonical Nf-Κβ Signaling

Hypoxia-Mediated Complement 1q Binding Protein Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates the PKC-NF-κB-VCAM-1 Signaling Pathway

Abstract P4-08-23: ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

Targeting Hypoxia and HIF1α in Triple-Negative Breast Cancer: New Insights from Gene Expression Profiling and Implications for Therapy

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway

Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer

Abstract P3-05-46: Scrna-Seq Profiling Reveals Different Tumor Immune-Microenvironment in Triple Negative Breast Cancer and Decodes Pivotal Role of THBS1- SDC1 Axis in Tumor Metastasis

HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer

CCT6A and Triple-Negative Breast Cancer Metastasis: Activating the AKT/MDM2/P53 Pathway

Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer

Hypoxia-mediated activation of hypoxia-inducible factor-1α in triple-negative breast cancer: A review

Identification of hypoxia-immune-related signatures for predicting immune efficacy in triple-negative breast cancer

Abstract 2789: NCAPG promotes triple-negative breast cancer stemness by a positive feedback loop with HIF-1α

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy

BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways

Dissection of triple-negative breast cancer microenvironment and identification of potential therapeutic drugs using single-cell RNA sequencing analysis

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

C1QBP Mediates Breast Cancer Cell Proliferation and Growth via Multiple Potential Signalling Pathways